Zolpidem is a potent stoichiometry-selective modulator of α1β3 GABA A receptors: Evidence of a novel benzodiazepine site in the α1-α1 interface

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Che Has, Ahmad Tarmizi ^a   Absalom, Nathan ^a   Van Nieuwenhuijzen, Petra S ^a   Clarkson, Andrew N ^a,b   Ahring, Philip K ^a   Chebib, Mary ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; GABRA1 PROTEIN, HUMAN; GABRB3 PROTEIN, HUMAN; PYRIDINE DERIVATIVE; ZOLPIDEM;

ANIMAL; BINDING SITE; CHEMISTRY; GENETICS; HUMAN; METABOLISM; XENOPUS LAEVIS;

ANIMALS; BINDING SITES; GABA-A RECEPTOR AGONISTS; HUMANS; PYRIDINES; RECEPTORS, GABA-A; XENOPUS LAEVIS;

EID: 84977103257     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28674     Document Type: Article

References (61)

1. Chebib, M. & Johnston, G. A. GABA-Activated ligand gated ion channels: medicinal chemistry and molecular biology. J Med Chem 43, 1427-1447 (2000).
2. Farrant, M. & Nusser, Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci 6, 215-229 (2005).
3. Sieghart, W. Structure, pharmacology, and function of GABAA receptor subtypes. Adv Pharmacol 54, 231-263 (2006).
4. Sieghart, W. Allosteric modulation of GABAA receptors via multiple drug-binding sites. Adv Pharmacol 72, 53-96 (2015).
5. Sancar, F., Ericksen, S. S., Kucken, A. M., Teissere, J. A. & Czajkowski, C. Structural determinants for high-Affinity zolpidem binding to GABAA receptors. Mol Pharmacol 71, 38-46 (2007).
6. Hanson, S. M., Morlock, E. V., Satyshur, K. A. & Czajkowski, C. Structural requirements for eszopiclone and zolpidem binding to the gamma-Aminobutyric acid type-A (GABAA) receptor are different. J Med Chem 51, 7243-7252 (2008).
7. Baur, R. & Sigel, E. Replacement of histidine in position 105 in the alpha(5) subunit by cysteine stimulates zolpidem sensitivity of alpha(5)beta(2)gamma(2) GABAA receptors. J Neurochem 103, 2556-2564 (2007).
8. Ramerstorfer, J., Furtmuller, R., Vogel, E., Huck, S. & Sieghart, W. The point mutation gamma 2F77I changes the potency and efficacy of benzodiazepine site ligands in different GABAA receptor subtypes. Eur J Pharmacol 636, 18-27 (2010).
9. Sanna, E. et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes. Eur J Pharmacol 451, 103-110 (2002).
10. Sigel, E. Mapping of the benzodiazepine recognition site on GABAA receptors. Curr Topics Med Chem 2, 833-839 (2002).
11. Ernst, M., Brauchart, D., Boresch, S. & Sieghart, W. Comparative modeling of GABAA receptors: limits, insights, future developments. Neurosci 119, 933-943 (2003).
12. Patat, A. et al. Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic. Clin Pharmacol Ther 56, 430-436 (1994).
13. Chen, Y. Y., Sy, H. N. & Wu, S. L. Zolpidem improves akinesia, dystonia and dyskinesia in advanced Parkinsons disease. J Clin Neurosci 15, 955-956 (2008).
14. Hall, S. D. et al. GABA-mediated changes in inter-hemispheric beta frequency activity in early-stage Parkinsons disease. Neurosci 281C, 68-76 (2014).
15. Prokic, E. J. et al. Cortical oscillatory dynamics and benzodiazepine-site modulation of tonic inhibition in fast spiking interneurons. Neuropharmacol 95, 192-205 (2015).
16. Clauss, R., Sathekge, M. & Nel, W. Transient improvement of spinocerebellar ataxia with zolpidem. New Eng J Med 351, 511-512 (2004).
17. Chang, A. Y. & Weirich, E. Trial of Zolpidem, Eszopiclone, and Other GABA Agonists in a Patient with Progressive Supranuclear Palsy. Case Rep Med 2014, 107064 (2014).
18. Cope, D. W. et al. Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation. Eur J Neurosci 21, 3002-3016 (2005).
19. May, A. C., Fleischer, W., Kletke, O., Haas, H. L. & Sergeeva, O. A. Benzodiazepine-site pharmacology on GABAA receptors in histaminergic neurons. Br J Pharmacol 170, 222-232 (2013).
20. Gao, H. & Smith, B. N. Zolpidem modulation of phasic and tonic GABA currents in the rat dorsal motor nucleus of the vagus. Neuropharmacol 58, 1220-1227 (2010).
21. Khom, S. et al. Pharmacological properties of GABAA receptors containing gamma1 subunits. Mol Pharmacol 69, 640-649 (2006).
22. Buhr, A. & Sigel, E. A point mutation in the gamma2 subunit of gamma-Aminobutyric acid type A receptors results in altered benzodiazepine binding site specificity. Proc Nat Acad Sci 94, 8824-8829 (1997).
23. Brickley, S. G., Cull-Candy, S. G. & Farrant, M. Single-channel properties of synaptic and extrasynaptic GABAA receptors suggest differential targeting of receptor subtypes. J Neurosci 19, 2960-2973 (1999).
24. Sieghart, W. & Sperk, G. Subunit composition, distribution and function of GABAA receptor subtypes. Curr Topics Med Chem 2, 795-816 (2002).
25. Mortensen, M. & Smart, T. G. Extrasynaptic alphabeta subunit GABAA receptors on rat hippocampal pyramidal neurons. J Physiol 577, 841-856 (2006).
26. Bencsits, E., Ebert, V., Tretter, V. & Sieghart, W. A significant part of native gamma-Aminobutyric AcidA receptors containing alpha4 subunits do not contain gamma or delta subunits. J Biol Chem 274, 19613-19616 (1999).
27. Sinkkonen, S. T., Luscher, B., Luddens, H. & Korpi, E. R. Autoradiographic imaging of altered synaptic alphabetagamma2 and extrasynaptic alphabeta GABAA receptors in a genetic mouse model of anxiety. Neurochem Int 44, 539-547 (2004).
28. Walters, R. J., Hadley, S. H., Morris, K. D. & Amin, J. Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms. Nat. Neurosci. 3, 1274-1281 (2000).
29. Baur, R. et al. Covalent modification of GABAA receptor isoforms by a diazepam analogue provides evidence for a novel benzodiazepine binding site that prevents modulation by these drugs. J Neurochem 106, 2353-2363 (2008).
30. Ramerstorfer, J. et al. The GABAA receptor alpha + beta-interface: A novel target for subtype selective drugs. J Neurosci 31, 870-877 (2011).
31. Tretter, V., Ehya, N., Fuchs, K. & Sieghart, W. Stoichiometry and assembly of a recombinant GABAA receptor subtype. J Neurosci 17, 2728-2737 (1997).
32. Farrar, S. J., Whiting, P. J., Bonnert, T. P. & McKernan, R. M. Stoichiometry of a ligand-gated ion channel determined by fluorescence energy transfer. J Biol Chem 274, 10100-10104 (1999).
33. Boileau, A. J., Pearce, R. A. & Czajkowski, C. Tandem subunits effectively constrain GABAA receptor stoichiometry and recapitulate receptor kinetics but are insensitive to GABAA receptor-Associated protein. J Neurosci 25, 11219-11230 (2005).
34. Harpsoe, K. et al. Unraveling the high-and low-sensitivity agonist responses of nicotinic acetylcholine receptors. J Neurosci 31, 10759-10766 (2011).
35. Ahring, P. K. et al. Engineered alpha4beta2 nicotinic acetylcholine receptors as models for measuring agonist binding and effect at the orthosteric low-Affinity alpha4-Alpha4 interface. Neuropharmacol 92, 135-145 (2015).
36. Chua, H. C., Absalom, N. L., Hanrahan, J. R., Viswas, R. & Chebib, M. The Direct Actions of GABA, 2?-Methoxy-6-Methylflavone and General Anaesthetics at beta3gamma2L GABAA Receptors: Evidence for Receptors with Different Subunit Stoichiometries. PloS one 10, e0141359 (2015).
37. Kaur, K. H., Baur, R. & Sigel, E. Unanticipated structural and functional properties of δ-subunit-containing GABAA receptors. J Biol Chem 284, 7889-7896 (2009).
38. Saras, A. et al. Histamine action on vertebrate GABAA receptors: direct channel gating and potentiation of GABA responses. J Biol Chem 283, 10470-10475 (2008).
39. Hoerbelt, P. et al. Mutagenesis and computational docking studies support the existence of a histamine binding site at the extracellular beta3 + beta3-interface of homooligomeric beta3 GABA receptors. Neuropharmacol 108, 252-263 (2016).
40. Hosie, A. M., Dunne, E. L., Harvey, R. J. & Smart, T. G. Zinc-mediated inhibition of GABAA receptors: discrete binding sites underlie subtype specificity. Nat. Neurosci. 6, 362-369 (2003).
41. Pritchett, D. B. & Seeburg, P. H. Gamma-Aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem 54, 1802-1804 (1990).
42. Wieland, H. A. & Luddens, H. Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem 37, 4576-4580 (1994).
43. Baumann, S. W., Baur, R. & Sigel, E. Subunit arrangement of gamma-Aminobutyric acid type A receptors. J Biol Chem 276, 36275-36280 (2001).
44. Smart, T. G., Moss, S. J., Xie, X. & Huganir, R. L. GABAA receptors are differentially sensitive to zinc: dependence on subunit composition. Br J Pharmacol 103, 1837-1839 (1991).
45. Frederickson, C. J. et al. Synaptic release of zinc from brain slices: factors governing release, imaging, and accurate calculation of concentration. J Neurosci Methods 154, 19-29 (2006).
46. Frederickson, C. J. et al. Concentrations of extracellular free zinc (pZn)e in the central nervous system during simple anesthetization, ischemia and reperfusion. Experimental neurology 198, 285-293 (2006).
47. Qian, J. & Noebels, J. L. Visualization of transmitter release with zinc fluorescence detection at the mouse hippocampal mossy fibre synapse. J Physiol 566, 747-758 (2005).
48. Vogt, K., Mellor, J., Tong, G. & Nicoll, R. The actions of synaptically released zinc at hippocampal mossy fiber synapses. Neuron 26, 187-196 (2000).
49. Patel, B., Bright, D. P., Mortensen, M., Frolund, B. & Smart, T. G. Context-Dependent Modulation of GABAAR-Mediated Tonic Currents. J Neurosci 36, 607-621 (2016).
50. Cope, D. W. et al. Enhanced tonic GABAA inhibition in typical absence epilepsy. Nature medicine 15, 1392-1398 (2009).
51. Cope, D. W. et al. Abolition of zolpidem sensitivity in mice with a point mutation in the GABAA receptor gamma2 subunit. Neuropharmacol 47, 17-34 (2004).
52. Kharlamov, E. A., Downey, K. L., Jukkola, P. I., Grayson, D. R. & Kelly, K. M. Expression of GABAA receptor alpha1 subunit mRNA and protein in rat neocortex following photothrombotic infarction. Brain Res 1210, 29-38 (2008).
53. Liu, J. et al. Quantitative reverse transcription-polymerase chain reaction of GABAA alpha1, beta1 and gamma2S subunits in epileptic rats following photothrombotic infarction of neocortex. Epilepsy Res 52, 85-95 (2002).
54. Hiu, T. et al. Enhanced phasic GABA inhibition during the repair phase of stroke: A novel therapeutic target. Brain 139 (Pt 2), 468-80 (2016).
55. Raol, Y. H. et al. Enhancing GABAA receptor alpha 1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J Neurosci 26, 11342-11346 (2006).
56. Raol, Y. H. et al. Increased GABAA-receptor alpha1-subunit expression in hippocampal dentate gyrus after early-life status epilepticus. Epilepsia 47, 1665-1673 (2006).
57. Cohen, L., Chaaban, B. & Habert, M. O. Transient improvement of aphasia with zolpidem. New Eng J Med 350, 949-950 (2004).
58. Brefel-Courbon, C. et al. Clinical and imaging evidence of zolpidem effect in hypoxic encephalopathy. Ann Neurol 62, 102-105 (2007).
59. Clauss, R. P. et al. Cerebral blood perfusion after treatment with zolpidem and flumazenil in the baboon. Arzneimittel-Forschung 52, 740-744 (2002).
60. Karim, N. et al. 2?-Methoxy-6-methylflavone: A novel anxiolytic and sedative with subtype selective activating and modulating actions at GABAA receptors. Br J Pharmacol 165, 880-896 (2012).
61. Karim, N. et al. 3-Hydroxy-2?-methoxy-6-methylflavone: A potent anxiolytic with a unique selectivity profile at GABAA receptor subtypes. Biochem Pharmacol 82, 1971-1983 (2011).